Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Michael Martens PhD

Michael Martens PhD profile photo picture

Assistant Professor

Institution: Medical College of Wisconsin
Department: Institute for Health and Equity
Division: Biostatistics
Program: Research

Member of the Cancer Center

Publications (19)

  • Health-related quality of life in reduced-intensity hematopoietic cell transplantation based on donor availability in patients aged 50-75 with advanced myelodysplastic syndrome: BMT CTN 1102. (Cusatis R, Martens MJ, Nakamura R, Cutler CS, Saber W, Lee SJ, Logan BR, Shaw BE, Gregory A, D'Souza A, Hamilton BK, Horowitz MM, Flynn KE) Am J Hematol 2022 Oct 17 PMID: 36251401 SCOPUS ID: 2-s2.0-85142150726 10/18/2022    
  • A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial. (Bashir Q, Nishihori T, Pasquini MC, Martens MJ, Wu J, Alsina M, Anasetti C, Brunstein C, Dawson P, Efebera Y, Gasparetto C, Geller N, Giralt S, Hall AC, Koreth J, McCarthy P, Scott E, Stadtmauer EA, Vesole DH, Hari P) Transplant Cell Ther 2022 Jul 12 PMID: 35840087 07/16/2022    
  • Clinical Characteristics and Outcomes of COVID-19 in Pediatric and Early Adolescent and Young Adult Hematopoietic Stem Cell Transplant Recipients: A Cohort Study. (Bhatt NS, Sharma A, St Martin A, Abid MB, Brown VI, Diaz Perez MA, Frangoul H, Gadalla SM, Herr MM, Krem MM, Lazarus HM, Martens MJ, Mehta PA, Nishihori T, Prestidge T, Pulsipher MA, Rangarajan HG, Williams KM, Winestone LE, Yin DE, Riches ML, Dandoy CE, Auletta JJ) Transplant Cell Ther 2022 Oct;28(10):696.e1-696.e7 PMID: 35798233 PMCID: PMC9251957 SCOPUS ID: 2-s2.0-85136313619 07/08/2022    
  • Long term clinical outcomes and associated predictors of progression free survival in anal canal cancer (Beltrán Ponce SE, Erickson BA, Hall WA, Bedi M, Martens MJ, Siker M, Thomas J, George B, Ludwig K, Peterson C, Ridolfi T, Longo JM) Journal of Gastrointestinal Oncology February 2022;13(1):185-196 SCOPUS ID: 2-s2.0-85125562951 02/01/2022    
  • Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD. (Meyers G, Hamadani M, Martens M, Ali H, Choe H, Dawson P, Harris AC, van Hooren E, Klaassen W, Leifer E, MacMillan ML, van Oosterhout Y, Perez L, Pusic I, Vo P, Levine JE) Bone Marrow Transplant 2022 Feb;57(2):302-303 PMID: 34815518 PMCID: PMC8825705 SCOPUS ID: 2-s2.0-85119658579 11/25/2021    
  • Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. (Nakamura R, Saber W, Martens MJ, Ramirez A, Scott B, Oran B, Leifer E, Tamari R, Mishra A, Maziarz RT, McGuirk J, Westervelt P, Vasu S, Patnaik M, Kamble R, Forman SJ, Sekeres MA, Appelbaum F, Mendizabal A, Logan B, Horowitz M, Cutler C) J Clin Oncol 2021 Oct 20;39(30):3328-3339 PMID: 34106753 PMCID: PMC8791814 SCOPUS ID: 2-s2.0-85112086284 06/10/2021       22 Citations
  • Acute GVHD Diagnosis and Adjudication in a Multicenter Trial: A Report From the BMT CTN 1202 Biorepository Study. (Reshef R, Saber W, Bolaños-Meade J, Chen G, Chen YB, Ho VT, Ponce DM, Nakamura R, Martens MJ, Hansen JA, Levine JE) J Clin Oncol 2021 Jun 10;39(17):1878-1887 PMID: 33507810 PMCID: PMC8260916 SCOPUS ID: 2-s2.0-85108020505 01/29/2021       4 Citations
  • A unified approach to sample size and power determination for testing parameters in generalized linear and time-to-event regression models. (Martens MJ, Logan BR) Stat Med 2021 Feb 28;40(5):1121-1132 PMID: 33210321 PMCID: PMC8020892 SCOPUS ID: 2-s2.0-85096664064 11/20/2020       1 Citation
  • Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. (Pidala J, Hamadani M, Dawson P, Martens M, Alousi AM, Jagasia M, Efebera YA, Chhabra S, Pusic I, Holtan SG, Ferrara JLM, Levine JE, Mielcarek M, Anasetti C, Antin JH, Bolaños-Meade J, Howard A, Logan BR, Leifer ES, Pritchard TS, Horowitz MM, MacMillan ML) Blood 2020 Jan 09;135(2):97-107 PMID: 31738834 PMCID: PMC6952830 SCOPUS ID: 2-s2.0-85077761109 11/19/2019       32 Citations
  • Group sequential tests for treatment effect on survival and cumulative incidence at a fixed time point. (Martens MJ, Logan BR) Lifetime Data Anal 2020 Jul;26(3):603-623 PMID: 31729633 PMCID: PMC7365590 SCOPUS ID: 2-s2.0-85075483839 11/16/2019       1 Citation
  • Factors Associated With Successful Discontinuation of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation. (Pidala J, Martens M, Anasetti C, Carreras J, Horowitz M, Lee SJ, Antin J, Cutler C, Logan B) JAMA Oncol 2020 Jan 01;6(1):e192974 PMID: 31556923 PMCID: PMC6763979 SCOPUS ID: 2-s2.0-85072756041 09/27/2019       11 Citations
  • Low Information Omnibus (LIO) priors for dirichlet process mixture models (Shi Y, Martens M, Banerjee A, Laud P) Bayesian Analysis 2019;14(3):677-702 SCOPUS ID: 2-s2.0-85069995277 01/01/2019       7 Citations
  • A group sequential test for treatment effect based on the Fine-Gray model. (Martens MJ, Logan BR) Biometrics 2018 Sep;74(3):1006-1013 PMID: 29534294 PMCID: PMC6146968 SCOPUS ID: 2-s2.0-85043497709 03/14/2018       3 Citations
  • Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. (Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, Aljurf M, Ballen KK, Bajel A, Baron F, Battiwalla M, Beitinjaneh A, Cahn JY, Carabasi M, Chen YB, Chhabra S, Ciurea S, Copelan E, D'Souza A, Edwards J, Foran J, Freytes CO, Fung HC, Gale RP, Giralt S, Hashmi SK, Hildebrandt GC, Ho V, Jakubowski A, Lazarus H, Luskin MR, Martino R, Maziarz R, McCarthy P, Nishihori T, Olin R, Olsson RF, Pawarode A, Peres E, Rezvani AR, Rizzieri D, Savani BN, Schouten HC, Sabloff M, Seftel M, Seo S, Sorror ML, Szer J, Wirk BM, Wood WA, Artz A) Blood 2017 Aug 31;130(9):1156-1164 PMID: 28674027 PMCID: PMC5580273 SCOPUS ID: 2-s2.0-85028876059 07/05/2017       142 Citations
  • Comparing outcomes of matched related donor and matched unrelated donor hematopoietic cell transplants in adults with B-Cell acute lymphoblastic leukemia. (Segal E, Martens M, Wang HL, Brazauskas R, Weisdorf D, Sandmaier BM, Khoury HJ, de Lima M, Saber W) Cancer 2017 Sep 01;123(17):3346-3355 PMID: 28452054 PMCID: PMC5568918 SCOPUS ID: 2-s2.0-85018961928 04/30/2017       15 Citations
  • Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma. (Cornell RF, Bachanova V, D'Souza A, Woo-Ahn K, Martens M, Huang J, Al-Homsi AS, Chhabra S, Copelan E, Diaz MA, Freytes CO, Gale RP, Ganguly S, Hamadani M, Hildebrandt G, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Saad A, Usmani S, Vesole DH, Yared J, Mark T, Nieto Y, Hari P) Biol Blood Marrow Transplant 2017 Jan;23(1):60-66 PMID: 27789362 PMCID: PMC5182098 SCOPUS ID: 2-s2.0-85006371447 10/30/2016       14 Citations
  • Pretransplantation Exercise and Hematopoietic Cell Transplantation Survival: A Secondary Analysis of Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0902). (Wingard JR, Wood WA, Martens M, Le-Rademacher J, Logan B, Knight JM, Jacobsen PB, Jim H, Majhail NS, Syrjala K, Rizzo JD, Lee SJ) Biol Blood Marrow Transplant 2017 Jan;23(1):161-164 PMID: 27742574 PMCID: PMC5182134 SCOPUS ID: 2-s2.0-85006489235 10/16/2016       7 Citations
  • Patient-Reported Outcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic Stem Cell Transplantation: A Study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial. (Knight JM, Syrjala KL, Majhail NS, Martens M, Le-Rademacher J, Logan BR, Lee SJ, Jacobsen PB, Wood WA, Jim HSL, Wingard JR, Horowitz MM, Abidi MH, Fei M, Rawls L, Rizzo JD) Biol Blood Marrow Transplant 2016 Dec;22(12):2256-2263 PMID: 27565521 PMCID: PMC5116244 SCOPUS ID: 2-s2.0-84992110582 08/28/2016       17 Citations
  • Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival. (Dhakal B, D'Souza A, Martens M, Kapke J, Harrington AM, Pasquini M, Saber W, Drobyski WR, Zhang MJ, Hamadani M, Hari PN) Clin Lymphoma Myeloma Leuk 2016 Jul;16(7):379-86 PMID: 27160644 SCOPUS ID: 2-s2.0-84965053091 05/11/2016       15 Citations
  • Last update: 11/29/2022